Brian Wong

Biography

 Brian joined FLX Bio in 2015 from Five Prime Therapeutics, where he served as Senior Vice President, Research, and Head of Immuno-Oncology.  At Five Prime, he led the discovery of novel immuno-oncology therapeutics, one of which has progressed to clinical trials in combination with Bristol-Myers Squibb Co.'s (BMS) Opdivo™.  BMS has pledged more than $1 billion to exclusively license the program.   Prior to Five Prime, Brian served as Director of Research in the Inflammation Disease Biology Area at Roche Palo Alto from 2005 to 2009.  He led the development of Roche’s rheumatology discovery portfolio, consisting of more than 20 biologics and small-molecule programs in clinical phases from discovery to mid-stage development.  From 2000 to 2005, he held various leadership roles at Rigel Pharmaceuticals, where he identified and developed clinical candidates for allergic, autoimmune and respiratory disorders.    Brian received his M.D. from the Weill Cornell Medical College and his Ph.D. in Immunology from Rockefeller University under Dr. Yongwon Choi, Ph.D., a Howard Hughes Medical Institute Investigator, and in collaboration with Nobel Laureate Dr. Ralph Steinman, M.D.

Research Interest

 Biology Research, Immunology and Advancements